Tissue Factor Pathway Inhibitor (Tfpi) - An Update

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue , 1996, Pages 154-165

  Sandset, Per Morten ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Coagulation inhibitor; Heparin; Lipoproteins; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

BLOOD CLOTTING INHIBITOR; HEPARIN; LIPOPROTEIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

BLOOD CLOTTING; CONFERENCE PAPER; DISSEMINATED INTRAVASCULAR CLOTTING; HEMOPHILIA; HUMAN; PRIORITY JOURNAL; THROMBOSIS;

ANIMALS; ANTITHROMBINS; BLOOD COAGULATION; ENDOTHELIUM, VASCULAR; FACTOR VIIA; FACTOR XA; HEMOPHILIA A; HEPARIN; HUMANS; LIPOPROTEINS; LIPOPROTEINS, LDL; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS;

EID: 0029853894     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217293     Document Type: Article

References (69)

1. Hjort PF: Intermediate reactions in the coagulation of blood with tissue thromboplastin. Scand J Clin Lab Invest 1957; 9 (Suppl 27): 1-182.
2. Sanders NL, Bajaj SP. Zivelin A, Rapaport SI: Inhibition of tissue factor/factor Vila activity in plasma requires factor X and an additional plasma component. Blood 1985: 66: 204-212.
3. Hubbard AR. Jennings CA: Inhibition of tissue factor-factor VII complex: Involvement of factor Xa and lipoproteins. Thromb Res 1986; 46:527-537.
4. Broze GJ, Miletich JP: Characterization of the inhibition of tissue factor in serum. Blood 1987; 69: 150-155.
5. Sandset PM, Abildgaard U, Pettersen M: A sensitive ehromogenic substrate assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res 1987; 47: 389-400.
6. Wun T-C, Kretzmer KK. Girard TJ, Miletich JP, Broze GJ: Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 13: 6001-6004.
7. Rao LVM, Rapaport SI: Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 1987; 69: 645-651.
8. Girard TJ. Warren LA. Novotny WF, Likert KM. Brown SG, Miletich JR. Broze GJ: Functional significance of the Kunitz type inhibitor domains of lipoprotein associated coagulation inhibitor. Nature 1989; 338: 518-520.
9. Broze JR Jr: Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-93.
10. Rapaport SI, Rao LVM: The tissue factor pathway: How it has become a prima ballerina. Thromb Haemost 1995; 74: 7-17.
11. Repke D, Gemmell CH, Guha A, Turitto VT, Broze GJ Jr, Nemerson Y: Hemophilia as a defect of the tissue factor pathway of blood coagulation: Effects of factos VIII and IX on factor X activation in a continuous-flow reactor. Proc Natl Acad Sci USA 1990;87:7623-7627.
12. Bajaj MS, Kuppuswany MN, Saito H, Spitzer SG. Bajaj SP: Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principle site of its synthesis. Proc Natl Acad Sci USA 1990; 87: 8869-8873.
13. Werling RW. Zacharski LR, Kisiel W. Bajaj SP, Memoli VA. Rousseau SM: Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost 1993; 69: 366-369.
14. Van der Logt CPE, Dirven RJ. Reitsma PH. Bertina RM: Expression of tissue factor and tissue factor pathway inhibitor in monocytes in response to bacterial lipopolysaccharide and phorboles-ter. Blood Coagul Fibrinol 1994; 5: 211-220.
15. McGee MP, Foster S, Wang X; Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes. A potential mechanism for localized control of blood coagulation. J Exp Med 1994; 179: 1847-1854.
16. Tyson DR, Kuppuswamy MN, Broze GJ Jr, Bajaj SP: Revised DNA sequence of exon I and 5' flanking region of the human tissue factor pathway inhibitor gene. Thromb Res 1993; 70: 269-273.
17. Warn-Cramer BJ. Almus FE, Rapaport SI: Studies of the factor Xa-dependent inhibitor of factor Vlla/tissue factor (extrinsic pathway inhibitor) from cell supernates of cultured human humbili-cal vein endothelial cells. Thromb Haemost 1989: 61: 101-105.
18. Lupu C, Lupu F, Dennehy U, Kakkar VV, Scully MF: Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vase Biol 1996; 15: 2055-2062.
19. Sandset PM, Abildgaard U, Larsen ML: Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988, 50, 803-813.
20. Broze GJ Jr, Girard TJ, Novotny WF: Regulation of blood coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990; 29: 7539-7546.
21. Wesselschmidt R. Likert K, Girard T. Wun TC. Broze GJ Jr. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood 1992; 79: 2004-2010.
22. Wesselschmidt R. Likert K, Huang ZF, MacPhail L. Broze GJ Jr: Structural requirements for tissue factor pathway inhibitor interactions with Factor Xa and heparin. Blood Coagul Fibrinol 1993; 4: 661-669.
23. Kojima T, Katsumi A. Yamazaki T. Muramatsu T. Nagasaka T, Ohsumi K. Saito H: Human ryu-docan from endothelium-like cells binds basic fibroblast growth factor, midkine, and tissue factor pathway inhibitor. J Biol Chem 1996; 271: 5914-5920.
24. Iversen N, Sandset PM, Abildgaard U, Torjesen PA: Binding of tissue factor pathway inhibitor (TFPI) to endothelial cells-Influence of glycosaminoglycans. Abstract 14th International Congress on Thrombosis, Montpellier. France. 1996.
25. Palmier MO. Hall LJ, Reisch CM. Baldwin MK. Wilson AG, Wun TC: Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thromb Haemost 1992; 68: 33-36.
26. Bregengaard C, Nordfang O, Ostergaard, P, Petersen JGL, Meyn G, Diness V, Svendsen O, Hedner U: Pharmacokinetics of full-length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits. Thromb Haemost 1993; 70: 454-457.
27. Warshawsky I. Broze GJ Jr, Schwarzt AL: The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci USA 1994; 91: 6664-6668.
28. Warshawsky I, Bu G, Mast A. Saffitz JE, Broze GJ Jr, Schwartz AL: The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 1995:95: 1773-1781.
29. Ho G, Toomey JR. Broze GJ Jr. Schwartz: Receptor-mediated endocytosis of coagulation factor Xa requires cell surface-bound tissue factor pathway inhibitor. J Biol Chem 1996; 271: 9497-9502.
30. Novotny WF, Brown SG, Miletich JP. Rader DJ, Broze GJ: Plasma antigen levels of the lipoprotein associated coagulation inhibitor in patient samples. Blood 1991, 78, 387-393.
31. Hubbard AR, Weller LJ, Gray E: Measurement of tissue factor pathway inhibitor in normal and post-heparin plasma. Blood Coagul Fibrinolysis 1994, 5:819-823.
32. Novotny WF, Girard JP, Miletich JP, Broze, GJ Jr: Purification and characterization of the lipoprotein associated coagulation inhibitor from human plasma. J Biol Chem 1989; 264: 18832-18837.
33. Hansen J-B. Huseby NE, Sandset PM, Svensson B. Lyngmo V, Nordoy A: Tissue factor pathway inhibitor and lipoproteins: Evidence for association with and regulation by LDL in human plasma. Arterioscl Thromb 1994; 14: 223-229.
34. Hansen J-B. Huseby KR. Huseby NE. Sandset PM. Hanssen T-A, Nordoy A: Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arterioscl Thromb Vase Biol 1995; 15,879-885.
35. Novotny WF. Girard JP. Miletich JP. Broze GJ: Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 1988, 72: 2020-2025.
36. Lojewski B, Bacher P, Jeske W, Fareed J: Molecular weight dependence on the release of tissue factor pathway inhibitor after subcutaneous and intravenous actions of heparins. Thromb Haemost 1993; 69; 1174C (abstr).
37. Zitoun D, Bara L. Bloch M-F, Samama MM: Plasma TFPI activity after intravenous injetion of pentasaccharide (PS) and unfractionated heparin in rabbits. Thromb Res 1994: 75: 577-580.
38. Lindahl AK, Sandset PM, Abildgaard U: The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinol 1992; 3: 439-449.
39. Valentin S, Larnkjer A, Ostergaard P, Nielsen JI, Nordfang O: Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res 1994; 75:173-183.
40. Ariens RAS, Faioni EM. Mannucci PM: Repeated release of the tissue factor pathway inhibitor. Thromb Haemost 1994; 72: 327-328.
41. Hansen J-B, Sandset PM. Huseby KR, Huseby N-E, Nordoy A: Depletion of endothelial-associated and circulating tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Abstract 14th International Congress on Thrombosis. Montpellier. France. 1996.
42. Broze GJ Jr, Lange GW, Duffin KL. MacPhail L: Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinol 1994; 5: 551-559.
43. Lindahl AK, Jacobsen PB, Sandset PM. Abildgaard U: Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagul Fibrinol 1991; 2: 713-721.
44. Sandset PM, Larsen ML, Abildgaard U, Lindahl AK. Odegaard OR: Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): Levels in the normal population and relation ot cholesterol. Blood Coagul Fibrinol 1991;2:425-433.
45. Sandset PM, Lund H, Norseth J, Abildgaard U. Ose L: Treatment with hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscl Thromb 1989; 11:138-145.
46. Zitoun D, Bara L, Basdevant A, Samama MM: Levels of factor Vile associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias. Arterioscl Thromb Vase Biol 1996;1:77-81.
47. Lesnick P, Vonica A, Guerin M, Moreau M, Chapman MJ: Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arterioscl Thromb 1993: 13: 1066-1075.
48. Lesnik P. Dentan C. Vonica A, Moreau M. Chapman MJ: Tissue factor pathway inhibitor activity associated with LDL is inactivated by cell-and copper-mediated oxidation. Arterioscl Thromb Vase Biol 1995;15:1121-1130
49. Kowaka T, Abumiya T, Kimura T, Harada-Shiba M. Koh H, Tsushima M, Yamamoto A. Kato H: Tissue factor pathway inhibitor activity in huma plasma. Measurment of lipoprotein-associated and free forms in hyperlipidemia. Arterioscl Thromb Vase Biol 1995:15:504-510.
50. Hansen J-B. Sandset PM, Huseby KR. Huseby N-E, Nordoy A: Inhibition of TFP1 activity in the medium of cultured endothelial cells by low density lipoproteins (LDL). Abstract 14th International Congress on Thrombosis. Montpellier. France. 1996.
51. Abildgaard U, Lindahl AK, Sandset PM: Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. Haemostasis 1991;21:254-57.
52. Huang ZF. Wun T-C. Broze GJJr: Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993:268:26950-26955.
53. Jesty J, Wun T-C, Lorenz A: Kinetics of the inhibition of factor Xa and the tissue factor-factor Vila complex by the tissue factor pathway inhibitor in the presence and absence of heparin. Biochemistry 1994;33:12686-12694.
54. Enjyoji K. Miyata T, Kamikubo Y, Kato H: Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: A segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site. Biochemistry 1995;34:5725-5735.
55. Abildgaard U: Relative roles of tissue factor pathway inhibitor and antithrombin in the control of thrombogenesis. Blood Coag Fibrinol 1995, 6, S45-S49.
56. Jesty J, Lorenz A, Rodrigues J, Wun T-C: Initiation of the tissue factor pathway of coagulation in the presence of heparin: Control by antithrombin III and tissue factor pathway inhibitor. Blood 1996;87:201-2307.
57. Rao LVM, Rapaport SI, Hoang AD: Binding of factor Vila to tissue factor permits rapid antithrombin III/heparin inhibition of factor Vila. Blood 1993:81:2600-2607.
58. Lawson JH, Butenas S, Ribarik N, Mann KG: Complex-dependent inhibition of factor Vila by antithrombin III and heparin. J Biol Chem 1993;268:767-770.
59. Rao LVM, Nordfang O, Hoang AD, Pendhurti U: Mechanism of antithrombin III inhibition of factor Vlla/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibi-tor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 1995;85:121-129.
60. Sandset PM. Warn-Cramer BJ, Maki SL, Rapaport SI: Immunodepletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 1991;88:708-712.
61. Sandset PM, Warn-Cramer BJ, Maki SL, Rapaport SI: Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction. Blood 1991;78:1496-1502.
62. Day KC, Hoffman LC, Palmier MO, Kretzmer KK. Huang MD, Pyla EY, Spokas E, Broze GJ Jr, Warren TG, Wun T-C: Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. Blood 1990;76:1538-1545.
63. Bregengaard C, Nordfang O, Wildgoose P, Svendsen O, Hedner U, Diness V: The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits. Blood Coagul Fibrinolysis 1993;4:699-706.
64. Creasy AA, Chang ACK, Feigen L, Wun T-C, Taylor FB, Hinshaw LB: Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993;91:2850-2860.
65. Spokes EG, Wun T-C: Venous thrombosis produced in the vena cava of rabbits by vascular damage and stasis. JMP 1992; 27:225-232.
66. Holst J, Lindblad B, Bergqvist D, Nordfang O, Ostergaard P, Petersen JG, Nielsen G, Hedner U: Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis-a comparison with low molecular weight heparin. Thromb Haemost 1994;71:214-219.
67. Haskel EK, Torr SR, Day KC. Palmier MO. Wun T-C, Sobel BE, Abendschein DR: Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 1991,84:821-827.
68. Lindahl AK, Sandset PM, Thune-Wiiger M, Nordfang O. Sakariassen KS: Tissue factor pathway inhibitor prevents thrombus formation on procoagulant subendothelial matrix. Blood Coagul Fibrinolysis 1994;5:755-760.
69. Erhardtsen E. Ezban M, Madsen MT, Diness V, Glazer S, Hedner U, Nordfang O: Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis 1995;6:388-394.